I just want to add that Kepivance, the only approved drug for OM, charges $10K per cycle, but it's hardly effective. There are about 500K patients affected by OM each year. If B-OM charges the same as Kepivance, $10K x 500K = $5B in annual sales. I think B-OM will dominate the market due to its efficacy, delivery method (oral rinse) and lack of competitions.

Quote:

---

Assume CTIX could charge $5K per year for B-OM rinse and that only patients who develop OM would use it (the 400K patients). If my math is correct that is about $2B in sales if it becomes the SOC.

---